GEN-MKT-18-7897-A
Jan 18, 2024 | Biopharma, Blogs, Clinical, Environmental / Industrial, Food / Beverage, Forensic, Life Science Research, Pharma, Technology | 0 comments
Read Time: 5 minutes
Unplanned downtime is a formidable adversary that businesses across various industries strive to minimize. Defined as the unexpected interruption of regular operations, unplanned downtime can wreak havoc on productivity, profitability and customer satisfaction. In this article, we delve into the causes of unplanned downtime, its far-reaching consequences and strategies to mitigate its impact.
Causes
Consequences
Mitigation strategies
Conclusion
Unplanned downtime remains a persistent challenge for businesses but with strategic planning and proactive measures, its impact can be significantly reduced. From embracing advanced technologies for predictive maintenance to fortifying cybersecurity defences, organizations must prioritize resilience to safeguard their operations, reputation and bottom line.
Let our experienced teams help you to build a robust package of support products to keep your workflows on track and deliver on your customer promises and explore all of our services here.
You can also explore our integrated software platform solution for all SCIEX innovations; SCIEX OS software delivers data integrity, seamless usability and efficiency gains for your mass spectrometry workflows throughout your laboratory.
In biopharmaceutical development, sequence variants (SV) are considered an inherent risk of producing complex proteins in living systems. Sequence variants are unintended changes to the amino acid sequence of a biotherapeutic and can be caused by errors in transcription or translation in the host cell, or cell culture and process conditions. Detailed analysis of SVs is important in process and product development to ensure the drug’s safety and efficacy. Even low‑level sequence variants can have significant implications for product quality, safety, and efficacy, making their accurate detection and characterization a critical requirement across development, process optimization, and regulatory submission.
CE‑SDS remains a cornerstone assay for characterizing fragmentation, aggregation, and product‑related impurities in therapeutic proteins. UV detection has been the long‑standing standard. However, it frequently struggles with baseline noise, limited sensitivity for minor fragments, and subjective integration.
At SCIEX, innovation doesn’t stop at instruments; it extends to how you interact with your LC-MS/MS or CE systems every day. That’s why we’re excited to introduce the SCIEX Now spring 2026 improvements: a set of meaningful enhancements shaped directly by your feedback.
Posted by
You must be logged in to post a comment.
Share this post with your network